Shaping the future from the small scale: dry powder inhalation of CRISPR-Cas9 lipid nanoparticles for the treatment of lung diseases.

Simone P CarneiroAntonietta GrecoEnrica ChiesaIda Genta Olivia M Merkel

Published in: Expert opinion on drug delivery (2023)

Exploring the pulmonary administration to deliver CRISPR-Cas9 loaded in LNPs as a dry powder increases the chances to achieve high efficacy and reduced adverse effects. CRISPR-Cas9 loaded in LNP-embedded microparticles has not yet been reported in the literature but has the potential to reach and accumulate in target cells in the lung, thus, enhancing overall efficacy and safety.

Keyphrases

crispr cas
genome editing
drug delivery
induced apoptosis
cancer therapy
pulmonary hypertension
cell cycle arrest
wound healing
endoplasmic reticulum stress
signaling pathway
cell death
cell proliferation
risk assessment
combination therapy
smoking cessation
walled carbon nanotubes
replacement therapy